EuroBiotech: More Articles of Note


> Nanobiotix created a subsidiary, Curadigm, to step up the use of nanoparticles to improve drug safety and bioavailability. Statement 

> Freeline posted preclinical data on its Fabry disease gene therapy. A single dose of the therapy sent GLA levels up to 1,061-fold higher than those of wild-type mice. Release 

> Transgene completed enrollment in a phase 2 trial that is testing TG4010 in combination with Opdivo. The milestone sets Transgene up to report primary endpoint data later this year. Statement  

> Mereo BioPharma posted six-month data from the open-label arm of a phase 2b trial in brittle bone disease. The data suggest setrusumab may improve bone density when Mereo reports data from the full study later this year. Statement 

> Orchard Therapeutics secured the worldwide license to an autologous hematopoietic stem cell gene therapy program for the treatment of Mucopolysaccharidosis Type I. Release  

> F-star completed the dose escalation phase of its FS118 study without seeing dose-limiting toxicities. Release